Cancer Research UK and the American Association for Cancer Research (AACR) are launching a new international alliance dedicated to accelerating progress against cancer.
News
Rigel bags first FDA approval
Rigel Pharmaceuticals has bagged its first FDA approval, with a green light to market Tavalisse for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have failed to respond to previous treatment.
US expands use of Shire’s Vonvendi
US regulators have expended the scope of Shire’s Vonvendi to include perioperative management of bleeding in adults with von Willebrand disease (VWD).
Amgen, Novartis’ migraine therapy impresses again
Amgen and Novartis’ closely watched experimental migraine therapy Aimovig has impressed again in late stage trials, this time hitting targets in patients for which other preventative treatments failed to work or weren’t tolerated.
BMS’ Opdivo/Yervoy combo cleared for kidney cancer
US regulators have approved a combination of Bristol-Myers Squibb’s immunotherapy drugs Opdivo and Yervoy as a first-line treatment for patients with advanced renal cell carcinoma.
Keytruda/chemo combo cut risk of death in NSCLC
MSD has unveiled further data from a trial showing that a combination of Keytruda and chemotherapy significantly improved overall survival in patients with metastatic non-squamous non-small-cell lung cancer (NSCLC).
Oxford Uni, Boehringer, Lilly link to test Jardiance in kidney disease
Boehringer Ingelheim and Eli Lilly are linking with Oxford University to assess the effect of SGLT2 inhibitor Jardiance on kidney disease and cardiovascular death.
BMS ties with Janssen on Factor XIa inhibitor programme
Bristol-Myers Squibb and Johnson & Johnson group Janssen have announced a deal to work together on a Factor XIa (FXIa) inhibitor programme.
Sanofi to sell generics unit for 1.9 billion Euros
Global investment group Advent International says it has entered into exclusive negotiations to buy Sanofi’s generics arm Zentiva for 1.9 billion Euros ($2.4 billion).
AZ’ Tagrisso offers sustained benefit in lung cancer
AstraZeneca says that the “unprecedented progression-free survival benefit” of Tagrisso when used as a first line treatment for lung cancer is sustained through subsequent lines of therapy.
Keytruda prolongs recurrence-free survival in melanoma, study shows
MSD and the European Organisation for Research and Treatment of Cancer (EORTC) have released new data showing that the anti-PD-1 therapy Keytruda significantly prolonged recurrence-free survival (RFS) in patients with high-risk stage III melanoma.
Shire sells oncology unit to Servier for $2.4bn
Dublin, Ireland-based Shire is selling its oncology unit to France’s Servier in a deal worth $2.4 billion.
MPs criticise NHS Digital/Home Office data sharing deal
The Health and Social Care Committee has voiced “serious concerns” about NHS Digital’s ability to protect patient data, after reviewing its Memorandum of Understanding with the Home Office that allows data sharing to trace immigration offenders.
Seats filling up fast at International Clinical Researcher of the Year
Get yours now before it’s too late!
UK study to investigate kidney disease progression
A large-scale observational study of chronic kidney disease (CKD) is due to launch in general practices this month, involving 3,205 Oxfordshire residents and led by Oxford University researchers.
